We evaluated the association of TLR2 (-196 to -174 Ins/Del) and TLR3 (1377 C>T) as potential risk factors for nasopharyngeal carcinoma (NPC) in Tunisians.
Introduction
Nasopharyngeal carcinoma (NPC) is emerging as a global public health problem (1, 2) . NPC is a malignant tumor of the head and neck region, with a strong potential for metastasis at early stages of the disease. NPC is a multifactorial disease, and its development and progression is influenced by environmental, viral, and genetic factors (3, 4) . These include high intake of dietary salt, smoking, and Epstein-Barr virus infection (5) . Altered proinflammatory and antiinflammatory mechanisms were also linked with cancer, including NPC (6, 7) .
Given their critical role in regulating innate and acquired immunity, and as biomarkers of infectious pathogens and cancer debris, toll-like receptors (TLRs) were described as key players in the pathogenesis and progression of NPC (8, 9) . Dysregulation of TLR signaling imparts a higher risk of the development of chronic inflammatory diseases and cancers (10) , in which TLR gene polymorphisms contribute to this dysregulation and thus to disease susceptibility and progression, including cancers. Accordingly, TLR gene variants were proposed to serve as biomarkers of altered cancer risk (11, 12) . These included the -196 to -174 chromosome 4q32 22-bp insertion/deletion (Ins/Del) polymorphism in the promoter region, which alters TLR2 promoter activity and thus its level of expression (13) . In addition, a nonsynonymous 1377C>T polymorphism in exon 4 of the TLR3 gene (chromosome 4) was shown to affect receptor-ligand interaction by altering the TLR3 ectodomain and thus functionally impairing the receptor (14) . However, the relationship between the contribution of TLR2 Ins/Del and TLR3 1377C>T polymorphisms and cancer risk remains unclear (15, 16) .
The present study aimed to study the association of TLR2 (-196 to -174 Ins/Del) and TLR3 (1377 C>T; rs3775290) polymorphisms with NPC in Tunisians, in view of their potential use as biomarkers to evaluate cancer risk.
Materials and methods

Study subjects
Between November 2012 and October 2015, 137 NPC patients from North Tunisia were recruited from the Salah Azeiz Oncology Institute (Tunisia). NPC diagnosis was established by clinical examination and histopathology. Confirmation of undifferentiated carcinoma of nasopharyngeal type (UCNT) was based on the simplified World Health Organization (WHO) classification for NPC (17) . Tumors were staged according to American Joint Committee on Cancer TNM staging system [T (tumor), size of the original primary tumor; N (nodes), regional lymph nodes, M = distant metastasis] (18) .
The control group comprised 164 unrelated blood donors (102 males and 62 females, mean age 48.6 ± 11.2 years), who were free of chronic disease, history of malignancy, drug allergies, hypertension, diabetes, or cardiovascular disease and were matched for sex and age with NPC patients. Controls were recruited from the Military Hospital, Tunisian Center of Maternity and Neonatology, and the Dispenser of Ettadhamen City. Demographic and clinical data were collected from patients and controls using a unified questionnaire. All subjects were asked to sign a consent form, agreeing to participate in the study, after all institutional ethics requirements were met.
TLR genotyping
Total genomic DNA was extracted from the peripheral blood of study participants using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). Determination of TLR2 -196 to -174 Ins/Del polymorphism was performed by PCR as previously described (19) , while TLR3 (1377C>T; rs3775290) genotyping was determined by PCR-restriction fragment length polymorphism (RFLP) analysis, as previously described (20) .
Statistical analysis
Statistical analysis was performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA) and Vassar Stats (http:// vassarstats.net/). Hardy-Weinberg equilibrium (HWE) was calculated for the tested variants in patients and controls. Student's t-test was used for variables with normal distribution (mean ± SD), while Pearson's chisquare test and Fisher's exact test (for low numbers of patients/controls) were used to analyze the association between TLR2 Ins/Del and TLR3 (1377C>T) and NPC development. Results were expressed as P-values, odds ratios (ORs), and 95% confidence intervals (CIs); P < 0.05 was considered statistically significant. Logistic regression was also performed to test the association between genotypes and NPC exposure, after adjusting for smoking and sex. Haplotype reconstruction was performed using SNPstats software (www.bioinfo.iconcologia.net/ SNPstats/).
Ethics
The study protocol was approved by the Ethics Committee of Salah Azeiz Oncology Institute.
Results
Clinical parameters of NPC cases
The demographic and clinical characteristics of NPC patients and controls are summarized in Table 1 . Study subjects comprised 137 patients (98 males and 39 females; mean age 46.3 ± 13.8 years) and 164 control subjects (102 males and 62 females; mean age 48.6 ± 11.2 years). All NPC patients underwent confirmation of UCNT, of whom 57 patients (41.6%) had T1-T2 tumor size, while the remaining 80 (58.4%) had T3-T4. In addition, 55 (40.1%) of NPC patients presented with either no regional lymph node metastasis or unilateral lymph node metastasis (N0-N1), while 82 (59.9%) had N2-N3. TNM staging identified 25 patients (18.2%) to be diagnosed at stage II and 112 (81.8%) at stages III-IV; distant metastasis was confirmed in only seven patients (5.1%).
Distribution of TLR2 (-196 to -174 Del) polymorphism
The distribution of TLR2 genotypes in controls was consistent with HWE. Table 2 displays TLR2 Ins/Del genotype and minor allele frequencies among study subjects. The frequency of the TLR2 Del/Del genotype was significantly higher in NPC patients compared to control subjects (19.7% vs. 9.1%, P = 0.004). After adjustment for smoking (P < 0.001) and sex (P = 0.027), data from logistic regression analysis showed that the TLR2 Del/Del genotype is positively associated with NPC risk [adjusted OR = 2.40 (1.14-5.05), P = 0.020].
Positive association with NPC risk was seen when a comparison was made between patients and controls for the frequency of TLR2 Del-containing genotypes (Ins/Del + Del/Del) versus noncarriers (Ins/Ins) [OR (95% CI) = 2.07 (1.27-3.37), P = 0.003] ( Table 2 ). Logistic regression confirmed that TLR2 Del allele carriers were more susceptible than noncarriers to develop NPC [adjusted OR = 1.83 (1.08-3.09), P = 0.024], which appeared to be independent of sex (P = 0.054). On the other hand, the carriage of the TLR2 minor (Del) allele was positively associated with a risk of NPC [30.6% vs. 17.3%, P < 0.001, OR (95% CI) = 2.10 (1.43-3.08)].
Distribution of TLR3 1377 C>T polymorphism
The distribution of TLR3 1377 C>T genotypes was consistent with HWE in patients and controls (P > 0.05). The genotype and minor allele frequencies of TLR3 1377 C>T polymorphism in NPC patients and healthy controls are listed in Table 2 . No significant differences were seen in frequencies between NPC patients and controls, indicating a lack of association with NPC. 
Association of TLR2 and TLR3 variants and clinical parameters
The association between TLR2 Ins/Del and TLR3 1377 C>T polymorphisms and clinical parameters, including tumor size, lymph nodes, metastasis, and TNM stage, are listed in Tables 3 and 4 . There was a lack of association of the studied polymorphisms with the examined clinical characteristics.
Linkage disequilibrium in TLR2/TLR3 gene and association with NPC risk
Since both the TLR2 and TLR3 genes are located on chromosome 4, we calculated the pairwise linkage disequilibrium (LD) values (D' and r 2 values) for the analyzed polymorphisms. The low D' (<0.1) and r 2 (<0.01) values indicate that the TLR2 Ins/Del polymorphism and TLR3 rs3775290 were in low LD. Data from Table 5 indicate that of the four possible haplotypes, the frequency 
Discussion
The study of candidate gene polymorphisms as potential biomarkers of cancer risk has facilitated understanding the association between genotype/haplotype and disease, thus underscoring the contribution of specific gene variants to susceptibility to various cancers, including NPC. TLRs are potent immune modulators, modulate inflammatory responses, and are involved in regulating cell proliferation, survival, and removal of cancer debris (8, 9) . However, inconsistencies in the exact role of TLRs in cancer pathogenesis were reported. The present study examined the association of two common polymorphisms in TLR2 and TLR3 with the susceptibility to NPC. The TLR2 Ins/Del polymorphism alters TLR2 promoter activity, leading to decreased transcription of the TLR2 gene. No previous studies have investigated the likely association between this variant and NPC risk. We found that the TLR2 Del allele and TLR2 Del/Del genotype were significantly associated with increased risk of NPC and thus may represent candidate biomarkers for evaluating NPC risk. Consistent with our findings, it was previously shown that the TLR2 Ins/Del polymorphism was associated with a heightened risk of some cancers, such as breast cancer, gastric cancer, prostate cancer, hepatocellular cancer, and cervical cancer (21) (22) (23) (24) (25) .
The distribution of the TLR3 1377 C>T allele and genotypes was comparable between NPC patients and controls, thus challenging the role (if any) for this TLR3 variant in NPC pathogenesis. Mixed findings on the association of TLR3 1377C>T with different cancer types were reported. This was highlighted by the lack of association of rs3775290 with NPC in China (26) , bladder cancer in India (27) , prostate cancer in India (23) , and breast cancer in Croatia (28) . In contrast, an earlier study documented the association of the TLR3 1377C/C genotype with increased susceptibility to cervical cancer in Tunisian women (29) . Further controlled studies involving larger sample sizes and molecular approaches are required to clarify the exact contribution of this variant (if any) to the development and/ or evolution of different cancer types, including NPC.
Analysis of LD patterns between TLR2 and TLR3 polymorphisms identified the Del-T haplotype to be positively associated with NPC. To the best of our knowledge, this is the first study that investigated the possible linkage between these two polymorphisms and the risk of NPC, and as such we cannot compare our results to related studies. Additional studies investigating the linkage of these two variants, and possibly others in the TLR2 and TLR3 genes, with NPC and other tumors are needed to clarify the implication of TLR2 and TLR3 polymorphic loci as biomarkers to evaluate cancer risk.
Our study has some strengths, namely that the NPC patients and controls have a similar ethnic background, as they originated from North Tunisia, thus minimizing the contribution of racial/ethnic differences inherent in genetic association studies. In addition, NPC assessment involved questionnaire-based interviews and laboratory assessment, including histology screening, and hence cancer was ascertained. However, our study also had a few limitations, namely that the sample size was relatively low, thereby necessitating future studies involving a larger number of cases and controls so as to fully understand the contribution of TLR2 and TLR3 gene polymorphisms in NPC, as well as related malignancies.
In conclusion, our results demonstrate an increased risk of NPC with the TLR2 Del/Del genotype and Del-T TLR2 and TLR3 haplotype, suggesting their potential use as biomarkers to evaluate NPC risk in Tunisians. Future studies using a larger number of patients and controls with different backgrounds should improve the evaluation of TLR2 and TLR3 variants as biomarkers for NPC risk. We thank all blood donors and patients with NPC who participated in the present study. We are grateful to the staff of the Tunisian Salah Azaiz Oncology Institute for their help in the collection of blood samples. We also thank Prof Wassim Y Almawi for his critical evaluation of the manuscript. 
